Table 3.

Associations of serum levels of SP-D and KL-6 with subsequent risk of lung cancer

Lung cancer cases, n (%)Matched controls, n (%)Adjusted ORa(95% CI)Mutually adjusted ORb (95% CI)
SP-D, ng/mL
16.5–71.797 (18)146 (25)1.001.00
71.8–105.3120 (23)145 (25)1.25 (0.87–1.79)1.19 (0.83–1.72)
105.4–143.8122 (23)146 (25)1.17 (0.81–1.68)1.13 (0.79–1.63)
143.9–615.5193 (36)145 (25)1.87 (1.32–2.64)1.77 (1.24–2.51)
Ptrend = 0.0003Ptrend = 0.001
KL-6, μg/mL
178.8–231.098 (18)145 (25)1.001.00
231.1–325.7113 (21)146 (25)1.11 (0.77–1.59)1.08 (0.75–1.56)
325.8–465.7160 (30)145 (25)1.66 (1.17–2.35)1.60 (1.13–2.28)
465.8–4,225.9161 (30)146 (25)1.58 (1.11–2.25)1.43 (1.00–2.05)
Ptrend = 0.005Ptrend = 0.03
  • aSeparate models were used for each marker. Estimates were adjusted for age, sex, smoking status, time since quitting, cumulative smoking, and randomization year.

  • bA single model included quartiles of both markers. Estimates were adjusted for age, sex, smoking status, time since quitting, cumulative smoking, randomization year, and scarring on baseline chest X-ray.